palmitoylethanolamide.com.au
HomeResearchDaniela 2015

Effects of palmitoylethanolamide and silymarin combination treatment in an animal model of kidney ischemia and reperfusion

Daniela Impellizzeri, Giuseppe Bruschetta, Akbar Ahmad, Rosalia Crupi, Rosalba Siracusa, Rosanna Di Paola, Irene Paterniti, Marco Prosdocimi, Emanuela Esposito, Salvatore Cuzzocrea. Eur J Pharmacol. 2015;762:136-49.

Laboratory studyOther animalsWith silymarin

This study tested palmitoylethanolamide together with silymarin. Its results cannot be assigned to palmitoylethanolamide alone. More combination studies.

Design
Laboratory study
Subjects
Mice with bilateral kidney artery occlusion (30 minutes) followed by 6 hours of reperfusion
Dose used in the study
Silymarin (100, 30 or 10 mg/kg) or PEA (1 mg/kg) or PEA (1 mg/kg) plus silymarin (10 mg/kg), given into the abdomen 15 minutes before clamp release
Duration
30 minutes of ischaemia plus 6 hours of reperfusion
What was measured
Kidney dysfunction markers, tissue damage, neutrophil infiltration (myeloperoxidase), oxidative stress (malondialdehyde), NF-kB pathway and apoptosis markers.

What the authors reported

Silymarin alone reduced kidney dysfunction, tissue damage, neutrophil infiltration and oxidative stress in a dose-dependent way. The PEA plus silymarin combination, even at lower individual doses, produced a significantly larger effect than either alone, with greater inhibition of NF-kB and apoptosis pathways.

Limits of this study

A mouse model of surgically induced kidney ischaemia and reperfusion; it cannot show effect in people. Funding and conflicts not stated in the abstract.

Source

PubMed 25981305 · doi:10.1016/j.ejphar.2015.05.010

Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.